The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic (COVID-19)

February 26, 2024 updated by: Dr. Jonpaul ST Zee, Hong Kong Sanatorium & Hospital

The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic: A Descriptive Study of Patients With SARS-CoV-2 RT-PCR Performed

Hong Kong public healthcare system is facing tremendous pressure under the COVID-19 pandemic. As the virus spread in Hong Kong, Hong Kong Sanatorium & Hospital (HKSH) is one of the first private hospitals which immediately provide reliable and rapid COVID-19 test -- Reverse Transcription Polymerase Chain Reaction (RT-PCR). Early provision of the RT-PCR screening test for COVID-19 not only facilitates identification of COVID-19 but also contains the spread of the virus in the community and frontline medical staff.

Since description of role of private hospital in Hong Kong amid COVID-19 pandemic is lacking, this study will describe COVID-19 screening algorithm and methodology. A retrospective analysis on clinical characteristics, laboratory findings as well as outcome of patients who underwent COVID-19 test in HKSH is also performed.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

2510

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Hong Kong
      • Hong Kong, Hong Kong
        • Hong Kong Sanatorium & Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Subjects who underwent COVID-19 test in HKSH during the study period

Description

Inclusion Criteria:

  • Subjects who underwent COVID-19 test in HKSH during the study period

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Subjects underwent COVID-19 test
Subjects who underwent COVID-19 test in HKSH during the study period
Diagnostic test: COVID 19 Diagnostic Test
COVID 19 Diagnostic Test

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of asymptomatic subjects
Time Frame: 1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong
Proportion of asymptomatic subjects (%) who underwent COVID 19 test
1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of subjects with recent contact history
Time Frame: 1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong
Proportion of subjects (%) with recent contact history
1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong
Proportion of subjects with recent travel history
Time Frame: 1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong
Proportion of subjects (%) with recent travel history
1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hong Kong Sanatorium & Hospital

Investigators

  • Principal Investigator: Jonpaul Sze Tsing Zee, MBChB, Hong Kong Sanatorium & Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 11, 2020

Primary Completion (Actual)

July 31, 2020

Study Completion (Actual)

July 31, 2020

Study Registration Dates

First Submitted

June 1, 2020

First Submitted That Met QC Criteria

June 2, 2020

First Posted (Actual)

June 4, 2020

Study Record Updates

Last Update Posted (Actual)

February 28, 2024

Last Update Submitted That Met QC Criteria

February 26, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RC-2020-08

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID

Clinical Trials on COVID 19 Diagnostic Test

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe